BaroPace

Executive Summary

BaroPace is developing a novel closed-loop cardiac pacing system, PressurePace™, that adjusts pacemaker heart rate in real-time based on blood pressure. This technology aims to address Heart Failure with Preserved Ejection Fraction (HFpEF) and drug-resistant hypertension—large unmet medical needs affecting millions globally. By restoring physiologic pacing, the system has the potential to improve cardiac output, reduce hospitalizations, and enhance quality of life for patients who currently have limited treatment options. Founded in 2019 and based in San Francisco, the company is leveraging its proprietary algorithm to differentiate from conventional pacemakers.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Pivotal Clinical Trial65% success
• Q2 2026FDA Breakthrough Device Designation80% success